Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Have a body mass index (BMI) within the range of 18.0 to 30.0 kg/m2, inclusive, and a minimum weight of at least 50.0 kg~* Be a current recreational opioid user who has used opioids for non-therapeutic purposes (ie for psychoactive effects) at least 10 times in their lifetime~* Agree to use an approved method of contraception for the duration of the study unless surgically sterile or postmenopausal~* Be willing and able to abide by all study requirements and restrictions~* Additional criteria may apply~Exclusion Criteria:~* Have evidence of drug or alcohol dependence within the past 2 years~* Have a positive drug screen for opioids, amphetamines, cocaine, or benzodiazepines upon admission to the clinic~* Have a history of severe allergic reaction (including anaphylaxis) to any food, medication, or bee sting~* Be currently pregnant, breastfeeding, or planning to become pregnant during the study~* Currently have or have a history of allergy or hypersensitivity to opioid agonists, opioid antagonists or related drugs (eg, oxycodone, morphine, naltrexone, and naloxone)~* Have a positive test result for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)~* Have donated or lost more than 500 mL whole blood~* Additional criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- ALKS 5461 Dose 1 (Type: EXPERIMENTAL): Sublingual tablets
- ALKS 5461 Dose 2 (Type: EXPERIMENTAL): Sublingual tablets
- ALKS 5461 Dose 3 (Type: EXPERIMENTAL): Sublingual tablets
- Buprenorphine Dose 1 (Type: ACTIVE_COMPARATOR): Sublingual tablets
- Buprenorphine Dose 2 (Type: ACTIVE_COMPARATOR): Sublingual tablets
- Placebo (Type: PLACEBO_COMPARATOR): Sublingual tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).